Recommanded Tools
AbSeek™ encompasses antibody sequence analysis, structure and function prediction, lead optimization, de novo generation, and visualization, among others, covering all stages of antibody discovery and engineering from screening to optimization for efficient innovation.
Free Tools Limited Time
Sequence Analysis
Function Prediction
Lead Optimization
Structure Prediction
New
Molecule Generation

Features & Advantages
Integration
Combines multiple algorithms to provide a one-stop service that meets all needs in antibody discovery and engineering.
Expertise
Tailors UI and data visualization methods based on the characteristics of antibody data for better suitability.
Advancement
Continuously updates cutting-edge AI algorithms to ensure the platform's timeliness and advancement.
Data Security
Committed to providing users with a secure and reliable data environment, alleviating concerns about data leakage.
News
Cyagen Talk|AI-Powered Antibody Discovery: From HUGO-Ab Mice to Predictive Models
AbSeek™: Intelligent Antibody Computational Platform
2025-03-19
More >>【Frontier Express】Signal Transduction and Targeted Therapy | Antibody targeting membrane-proximal AXL epitope overcomes resistance to immune checkpoint inhibitors by remodeling the tumor microenvironment
2026-04-21
【Frontier Express】HemaSphere | Dynamics of Complete Response with the CD20 × CD3 Bispecific Antibody Odronextamab in Relapsed/Refractory Follicular Lymphoma
2026-04-21
【Frontier Express】Cell | IL17A and IL10 Bidirectionally Regulate Amygdala Neuronal Excitability to Modulate Anxiety Behavior
2026-04-20
【Frontier Express】Molecular Cancer | circNSD2 Promotes Triple-Negative Breast Cancer Metastasis and Immune Escape via the USP10/SRSF6/TPM1 Axis
2026-04-20
【Frontier Express】HemaSphere | Targeting S100A9 Restores Bone Marrow Microenvironment Function and Improves Erythropoiesis and Bone Mass
2026-04-19
【Frontier Express】Journal of Extracellular Vesicles | Single-Exosome Nano-Flow Cytometry Reveals Heterogeneity of EV Subpopulations Across Cell Sources and Pharmacological Interventions
2026-04-19
【Frontier Express】Nature Communications | Phase I/II Clinical Trial Expansion of VEGF-A and CXCL12 Dual Inhibition Combined with Radiotherapy for Newly Diagnosed Glioblastoma
2026-04-18






